New APIIC Initiative To Strengthen U.S. Pharma Supply Chain

The API Innovation Center (APIIC) has secured funding from the Administration for Strategic Preparedness and Response’s (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) to spearhead the production of three essential active pharmaceutical ingredients (APIs) crucial for treating asthma, diabetes, and anxiety disorders. The chosen APIs, known for their critical roles in U.S. healthcare and history of shortages, include — Albuterol (for asthma and respiratory issues), Desmopressin Acetate (for diabetes insipidus and blood clotting problems) and Lorazepam (for anxiety management).  

APIIC plans to use advanced manufacturing techniques and innovative research to bolster the U.S. pharmaceutical sector and enhance supply chain resilience. The project will receive $14 million from IBMSC, with APIIC contributing an additional $2.4 million. This investment represents a major step toward securing the U.S. pharmaceutical supply chain and strengthening national health security.

This initiative leverages APIIC's robust network of partners, which includes top universities, pharmaceutical producers, and KSM suppliers. By bringing together the cutting-edge resources and technologies from Mallinckrodt Specialty Generics, Apertus Pharmaceuticals, MilliporeSigma, and the University of Missouri–St. Louis (UMSL), APIIC aims to boost the quality, efficiency, and global standing of pharmaceutical manufacturing in the U.S. These strategic alliances create a powerful team, with each member contributing their specialized knowledge. APIIC will provide the necessary funding and support to maximize the potential of these advanced manufacturing technologies and expertise.